04.05.2015 • NewsDede WillamsBASFUmicore

Umicore Calls BASF’s Patent Breach Claim “Flawed and Erroneous”

Belgium-based battery materials technology leader Umicore has publicly responded to BASF's allegations that it breached the German chemical giant's patents for nickel-cobalt-manganese (NCM) cathode raw materials used in lithium-ion batteries for electric cars and portable electronic devices.

In its official response to the Wilmington, Delaware, USA, federal court hearing BASF's charges, the company called the complaint "flawed" and "erroneous."

Subsequently, in response to a question about the worst-case scenario outcome of the lawsuit during Umicore's earnings call, the company's CEO, Marc Grynberg, said: "There is no case and there is no worst case scenario to be considered.

"All products in our business do have freedom to operate and are not infringing on the BASF or any other patents and we can demonstrate that," Grynberg added.

Supported by Chicago-based Argonne National Laboratory, from which it licensed the patents, BASF in April filed suit in the Delaware court as well as with the US Federal Trade Commission (FTC).

The world's largest chemical producer also claims that Umicore has sold the technology to third parties, naming the US arm of Japan's Makita Corporation in the lawsuit.

According to BASF, the patent breach has cost it billions of dollars in potential sales and deprived it of the ability to compete as a supplier for electric car platforms expected to launch in 2016 and 2017. The German group plans to invest up to $500 million in its battery materials business up to 2020.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.